Repository logo
 
Publication

Thrombotic events and COVID-19 vaccines

2021-09Journal article Open access
Simple item page
dc.contributor.authorBrazete, C.
dc.contributor.authorAguiar, A.
dc.contributor.authorFurtado, I.
dc.contributor.authorDuarte, R.
dc.date.accessioned2023-10-31T10:13:01Z
dc.date.available2023-10-31T10:13:01Z
dc.date.issued2021-09
dc.description.abstractCOVID-19 vaccines are considered promising agents in the control of the pandemic. Although their safety was assessed in randomised clinical trials, severe adverse events (AEs) have been reported after large-scale administration. This study aims to evaluate thromboembolic AEs reported after vaccination in a real-world context and how they led to the interruption of vaccination campaigns. We also review the benefits and risks of the vaccines approved in the European Union and provide recommendations. A review of the literature was performed using Medline/PubMed electronic database as well as institutional and pharmacovigilance official reports. Our findings show that vaccine-induced prothrombotic immune thrombocytopenia has been suggested as a very rare AE associated with viral vector vaccines. Unusual thrombotic events combined with moderate-to-severe thrombocytopenia were reported mainly in women under 60 years of age. As safety signals emerged, Vaxzevria and Janssen´s COVID-19 vaccine campaigns have been paused while investigations proceed. On the other hand, the number of deep vein thrombosis and pulmonary embolism reports have not increased. Post-marketing surveillance indicated that mRNA vaccines are safe and should continue to be used. The thrombotic events report rate is not increased in people over 60 years. As they are at greater risk for COVID-19 complications and death, no vaccine restrictions are recommended in this group. Risk factors for vaccine-induced prothrombotic immune thrombocytopenia should be established so that evidence-based decisions can be made. Systematic monitoring of COVID-19 vaccine safety is essential to ensure that the benefits of vaccination outweigh the risks.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBrazete C, Aguiar A, Furtado I, Duarte R. Thrombotic events and COVID-19 vaccines. Int J Tuberc Lung Dis. 2021;25(9):701-707. doi:10.5588/ijtld.21.0298pt_PT
dc.identifier.doi10.5588/ijtld.21.0298pt_PT
dc.identifier.issn1027-3719
dc.identifier.issn1815-7920
dc.identifier.urihttp://hdl.handle.net/10400.16/2862
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherThe Unionpt_PT
dc.relation.publisherversionhttps://www.ingentaconnect.com/content/iuatld/ijtld/2021/00000025/00000009/art00007pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectvaccinespt_PT
dc.subjectthrombosispt_PT
dc.subjectreviewpt_PT
dc.titleThrombotic events and COVID-19 vaccinespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceFrancept_PT
oaire.citation.endPage707pt_PT
oaire.citation.issue9pt_PT
oaire.citation.startPage701pt_PT
oaire.citation.titleThe International Journal of Tuberculosis and Lung Diseasept_PT
oaire.citation.volume25pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Brazete-2021-Thrombotic-events-and-covid--vaccin.pdf
Size:
303.6 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

SINF - Artigos publicados em revistas indexadas na Pubmed/Medline